Director, MEG Lead Cardiovascular, Medical Evidence Generation

At Bristol Myers Squibb, our employees often ask, “Who are you working for?”—a question that fuels collaboration, accountability, and urgency in our work. Our purpose-driven culture inspires us to discover, develop, and deliver innovative medicines to prevail over serious diseases. We offer uniquely interesting and meaningful work, opportunities for growth, and a supportive environment that values inclusion, wellbeing, flexibility, and comprehensive benefits.

This is work that transforms the lives of patients, and the careers of those who do it.

The Director of Medical Evidence Generation in Medical Affairs, will lead strategy, development, and execution of robust evidence generation strategies for the Cardiovascular (CV) portfolio through Clinical Research Collaborations (CRCs), Medical Affairs Sponsored Studies (MAST), and Investigator-Sponsored Research Studies (ISRs), designed to inform clinical development, support product value, and underpin medical strategy across the product lifecycle. This will be a scientific and strategic leader collaborating across internal functions (Medical Strategy, RWE/Epidemiology, Clinical Operations, Regulatory, HEOR, Access & Value) and with external stakeholders including key opinion leaders (KOLs), academic partners, and data collaborators.

Responsibilities will include, but are not limited to, the following:

• Act as a trusted internal advisor to Alliance partners, BMS global and regional Medical Affairs, Clinical Development, Access & Value, Regulatory, and Commercial teams on evidence gaps, opportunities, and study strategy.
• Define and drive the integrated evidence generation strategy (IEP) aligned with Medical Affairs and overall product strategy, spanning clinical trials (Phase II/IV), real‑world evidence (RWE), non-interventional studies, registries, observational research, and health outcomes studies.
• Provide hands‑on scientific leadership in the design of clinical studies including Phase II/IV trials, Post‑marketing commitment studies, Investigator‑initiated and collaborative research as applicable.
• Lead or significantly contribute to protocol development as applicable, including Study design, Study objectives and endpoints, Eligibility criteria, Statistical considerations (in collaboration with Biostatistics), Operational feasibility.
• Be accountable for delivering CRCs, ISRs, and MASTs from concept ideation to governance approval and throughout the study lifecycle.
• Serve as a thought leader on evidence generation methodologies to ensure evidence plans are fit‑for‑purpose and impactful.
• Lead preparation and delivery of evidence generation proposals and updates including results to internal governance bodies and cross‑functional stakeholders.
• Apply strong understanding of GCP, ICH guidelines, and clinical trial governance to ensure compliant and high‑quality study execution.
• Partner with Clinical Operations and CROs to ensure studies are delivered on time, on budget, and with high data quality.
• Review and interpret clinical and real‑world data to ensure medical relevance and scientific integrity.
• Engage with key opinion leaders (KOLs), academic investigators, and external research partners to co‑develop high‑impact evidence.
• Participate in advisory boards, steering committees, and scientific forums as necessary.
• Collaborate with cross‑functional partners to ensure cohesive planning and execution of evidence generation activities across geographies and therapeutic areas.
• Oversee operational delivery of studies, ensuring scientific rigor, quality, compliance (GCP/SOP), timelines, and budgets.
• Contribute to scientific dissemination through publications, abstracts, congress presentations, and advisory boards.
• Contribute to the evolution of MEG therapeutic…